MCID: MLN008
MIFTS: 63

Melanoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Melanoma

MalaCards integrated aliases for Melanoma:

Name: Melanoma 12 25 37 29 55 6 43 44 15 63 40 73
Malignant Melanoma 12 25 15
Cutaneous Melanoma 25 73
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
MeSH 44 D008545
NCIt 50 C3224
SNOMED-CT 68 2092003
KEGG 37 H00038
ICD10 33 D03.9

Summaries for Melanoma

MedlinePlus : 43 Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Melanoma, also known as malignant melanoma, is related to squamous cell carcinoma, head and neck and lung cancer, and has symptoms including pruritus and exanthema. An important gene associated with Melanoma is FBN1 (Fibrillin 1), and among its related pathways/superpathways are Melanoma and MicroRNAs in cancer. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lung.

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

Genetics Home Reference : 25 Melanoma is a type of skin cancer that begins in pigment-producing cells called melanocytes. This cancer typically occurs in areas that are only occasionally sun-exposed; tumors are most commonly found on the back in men and on the legs in women. Melanoma usually occurs on the skin (cutaneous melanoma), but in about 5 percent of cases it develops in melanocytes in other tissues, including the eyes (uveal melanoma) or mucous membranes that line the body's cavities, such as the moist lining of the mouth (mucosal melanoma). Melanoma can develop at any age, but it most frequently occurs in people in their fifties to seventies and is becoming more common in teenagers and young adults.

Novus Biologicals : 56 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

PubMed Health : 63 About melanoma: We all have moles or other small lumps and bumps that are a different color to the rest of our skin. This is perfectly normal and usually nothing to worry about. It is only rarely skin cancer.Skin cancer comes in different forms. The main types are (malignant) melanoma, basal cell cancer (BCC) and squamous cell cancer (SCC). Basal cell cancer and squamous cell cancer are sometimes grouped together and referred to as non-melanoma skin cancer. Melanoma, which often looks like a very dark mole, is the most widely known type of skin cancer. This is probably because some types are dangerous and can spread very quickly throughout the body.

Wikipedia : 76 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 964)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 32.3 CXCL8 MIR205 MIR221 SPRY4-IT1
2 lung cancer 31.8 BANCR CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222
3 neuroblastoma 31.5 CASC15 MIR221 MIR23B MIR34A MIRLET7B
4 breast cancer 31.0 CDKN2B-AS1 CXCL8 MIR182 MIR193B MIR205 MIR221
5 pancreatic cancer 30.8 CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B MIR34A
6 glioma 30.8 CDKN2B-AS1 MIR221 MIR222 MIR34A PVT1 SPRY4-IT1
7 colorectal cancer 30.7 BANCR CDKN2B-AS1 MIR182 MIR221 MIR34A MIRLET7B
8 prostate cancer 30.7 CDKN2B-AS1 MIR182 MIR205 MIR221 MIR222 MIR23B
9 dermatomyositis 30.6 MIR221 MIR222
10 hepatocellular carcinoma 30.5 BANCR CASC15 CDKN2B-AS1 CXCL8 MIR182 MIR205
11 glioblastoma 30.5 MIR182 MIR221 MIR222 MIR23B MIR34A
12 gastric cancer 30.5 BANCR CASC15 CDKN2B-AS1 MIR221 MIR222 MIR34A
13 leukemia, acute myeloid 30.2 CDKN2B-AS1 MIR182 MIR221 MIR222 MIR23B MIRLET7B
14 ovarian cancer 30.2 CDKN2B-AS1 MIR182 MIR221 MIR222 PVT1 SPRY4-IT1
15 esophageal cancer 30.1 CDKN2B-AS1 CXCL8 MIR205 MIR34A PVT1
16 cervical cancer 30.1 CDKN2B-AS1 MIR23B MIRLET7B PVT1 SPRY4-IT1
17 thyroid cancer, nonmedullary, 1 30.0 BANCR MIR221 MIR222 MIR34A PVT1
18 bladder cancer 30.0 BANCR CDKN2B-AS1 MIR205 MIR221 MIR222 MIR23B
19 oral squamous cell carcinoma 30.0 MIR221 MIR23B MIR34A
20 leukemia, acute lymphoblastic 30.0 MIR221 MIR222 MIR23B MIRLET7B
21 osteogenic sarcoma 29.6 BANCR CDKN2B-AS1 PVT1
22 melanoma, cutaneous malignant 1 12.6
23 melanoma, uveal 12.5
24 acral lentiginous melanoma 12.5
25 skin melanoma 12.5
26 melanoma-pancreatic cancer syndrome 12.4
27 melanoma, cutaneous malignant 8 12.4
28 ocular melanoma 12.4
29 intraocular melanoma 12.4
30 digestive system melanoma 12.4
31 nodular malignant melanoma 12.4
32 melanoma-astrocytoma syndrome 12.4
33 mucosal melanoma 12.4
34 malignant spindle cell melanoma 12.4
35 primary melanoma of the central nervous system 12.4
36 amelanotic melanoma 12.3
37 melanoma-associated retinopathy 12.3
38 superficial spreading melanoma 12.3
39 melanoma, cutaneous malignant 2 12.3
40 melanoma, cutaneous malignant 3 12.3
41 melanoma, cutaneous malignant 5 12.3
42 melanoma, cutaneous malignant 6 12.3
43 melanoma, cutaneous malignant 9 12.3
44 lentigo maligna melanoma 12.2
45 melanoma, cutaneous malignant 4 12.2
46 melanoma, cutaneous malignant 7 12.2
47 melanoma, cutaneous malignant 10 12.2
48 choroid spindle cell melanoma 12.2
49 melanoma of soft tissue 12.2
50 dysplastic nevus syndrome 12.2

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


pruritus, exanthema

Drugs & Therapeutics for Melanoma

PubMedHealth treatment related to Melanoma: 63

After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.

FDA approved drugs:

(show all 11)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erivedge 18 49 VISMODEGIB Genentech January 2012
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
4
Mekinist 18 49 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
5
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15
6
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
7
Proleukin 18 49 ALDESLEUKIN Chiron January 1998
8
Sylatron 18 49 PEGINTERFERON ALFA-2B Merck April 2011
9
Tafinlar 18 49 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
10
Yervoy 18 49 IPILIMUMAB Bristol-Myers Squibb March 2011
11
Zelboraf 18 49 VEMURAFENIB Roche August of 2011

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 672)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
2
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
3
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
5
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
6
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
7
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
8
Nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 946414-94-4
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
10
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
12
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
13
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5330286 5005498
14
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
15
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
16
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
17
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
18
Pembrolizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
19
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
20
Etanercept Approved, Investigational Phase 4 185243-69-0
21
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
22
Citalopram Approved Phase 4 59729-33-8 2771
23
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 62-33-9, 60-00-4 6049
24
Pentetic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 67-43-6
25
Simvastatin Approved Phase 4 79902-63-9 54454
26
Adalimumab Approved Phase 4 331731-18-1 16219006
27
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1195765-45-7 44462760 44516822
28
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
29
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
30
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
31
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
32
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
33
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
34
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
35
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
36
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
37
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
38
Lapatinib Approved March 2007, Investigational Phase 4,Phase 3,Phase 2 388082-78-8, 231277-92-2 208908 9941095
39 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
41 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
42 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
46 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2,Not Applicable
48 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
50 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 2572)
# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
4 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
5 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
6 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
7 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
8 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
9 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
10 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
11 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
12 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
13 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
14 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
15 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
16 Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation Recruiting NCT03767660 Phase 4 Rapamycin
17 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
18 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
19 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
20 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
21 Flu Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
22 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
23 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Not yet recruiting NCT03715205 Phase 4 Pembrolizumab
24 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
25 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
26 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
27 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
28 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
29 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
30 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
31 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
32 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
33 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
34 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
35 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
36 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
37 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
38 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
39 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
40 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
41 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
42 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
43 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
44 Thymosin-α1 in Cancer-Related Fatigue Unknown status NCT02127268 Phase 3 Thymosin-α1
45 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
46 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years
47 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
48 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
49 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
50 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed NCT00091572 Phase 3 Temozolomide;Dacarbazine

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

# Genetic test Affiliating Genes
1 Melanoma 29

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

41
Skin, T Cells, Lung, Lymph Node, Brain, Liver, Testes

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 16865)
# Title Authors Year
1
Lesions Mimicking Melanoma at Dermoscopy Confirmed Basal Cell Carcinoma: Evaluation with Reflectance Confocal Microscopy. ( 30404078 )
2019
2
Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review. ( 30455614 )
2019
3
Melanoma and mastocytosis: is really only a coincidence? ( 30178486 )
2019
4
Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. ( 30546944 )
2019
5
Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells. ( 30551515 )
2019
6
Current controversies in early-stage melanoma: Questions on incidence, screening, and histologic regression. ( 30553298 )
2019
7
Current controversies in early-stage melanoma: Questions on management and surveillance. ( 30553299 )
2019
8
Laminaran from brown alga Dictyota dichotoma and its sulfated derivative as radioprotectors and radiosensitizers in melanoma therapy. ( 30553355 )
2019
9
Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma. ( 30557221 )
2019
10
Consecutive Case Series of Melanoma Sentinel Node Biopsy for Lymphoseek Compared to Sulfur Colloids. ( 30502241 )
2019
11
Receipt of sentinel lymph node biopsy for thin melanoma is associated with distance traveled for care. ( 30508289 )
2019
12
Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody. ( 30528803 )
2019
13
Diet-dependent toxicity of ipilimumab in metastatic melanoma. ( 30528806 )
2019
14
Reprogramming of Human Melanocytes and Melanoma Cells with Yamanaka Factors. ( 30535702 )
2019
15
Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. ( 30539467 )
2019
16
Expression and localization of absent in melanoma 2 in the injured spinal cord. ( 30539825 )
2019
17
Updates in Melanoma. ( 30466690 )
2019
18
Cutaneous Melanoma-A Review in Detection, Staging, and Management. ( 30497675 )
2019
19
Management of Early-Stage Melanoma. ( 30420071 )
2019
20
Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis. ( 30431060 )
2019
21
Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. ( 30447951 )
2019
22
The metastasis suppressor NME1 inhibits melanoma cell motility via direct transcriptional induction of the integrin beta-3 gene. ( 30458180 )
2019
23
Reversing effect of Lupeol on vasculogenic mimicry in murine melanoma progression. ( 30381268 )
2019
24
Gemcitabine nanoparticles promote antitumor immunity against melanoma. ( 30388589 )
2019
25
Guidelines of care for the management of primary cutaneous melanoma. ( 30392755 )
2019
26
Consumer Acceptance and Expectations of a Mobile Health Application to Photograph Skin Lesions for Early Detection of Melanoma. ( 30404081 )
2019
27
Anticancer activities of Zanthoxylum bungeanum seed oil on malignant melanoma. ( 30336305 )
2019
28
Synthesis of cinnamic amide derivatives and their anti-melanogenic effect in α-MSH-stimulated B16F10 melanoma cells. ( 30347330 )
2019
29
Highly sensitive detection of DNA hypermethylation in melanoma cancer cells. ( 30366258 )
2019
30
Myrtenal-induced V-ATPase inhibition - A toxicity mechanism behind tumor cell death and suppressed migration and invasion in melanoma. ( 30279148 )
2019
31
Harnessing the gatekeepers of glucocorticoids for chemoprevention of non-melanoma skin cancer. ( 30302860 )
2019
32
Using Advances in Skin Imaging Technology and Genomics for the Early Detection and Prevention of Melanoma. ( 30253394 )
2019
33
Anti-melanogenic effects of oyster hydrolysate in UVB-irradiated C57BL/6J mice and B16F10 melanoma cells via downregulation of cAMP signaling pathway. ( 30273735 )
2019
34
A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models. ( 30201332 )
2019
35
Association of Skin Examination Behaviors and Thinner Nodular vs Superficial Spreading Melanoma at Diagnosis. ( 29710122 )
2018
36
TR47, a PAR1-based peptide, inhibits melanoma cell migration inA vitro and metastasis inA vivo. ( 29196264 )
2018
37
Mucosal melanoma: clinical and genetic profile. ( 29797459 )
2018
38
Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis. ( 29104160 )
2018
39
Capsule Commentary on Robinson et al.: A Randomized Trial on the Efficacy of Mastery Learning on Primary Care Providers' Melanoma Opportunistic Screening Skills and Practice. ( 29450688 )
2018
40
High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. ( 29975414 )
2018
41
HMGA1 and MMP-11 Are Overexpressed in Human Non-melanoma Skin Cancer. ( 29374701 )
2018
42
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. ( 29973204 )
2018
43
Basal cell carcinoma and malignant melanoma cutaneous collision tumor. ( 29904313 )
2018
44
A Fluorescent Probe for Early Detection of Melanoma and Its Metas-tasis through Specifically Imaging Tyrosinase Activity in Mouse Model. ( 29975041 )
2018
45
Clinical patterns and management of primary mucosal melanoma: a single centre experience. ( 29388353 )
2018
46
Updates in the management of sinonasal mucosal melanoma. ( 29095708 )
2018
47
Robot-assisted laparoscopic surgery for abdominal metastatic melanoma mimicking a gastrointestinal stromal tumor: A case report and review of the literature. ( 29952974 )
2018
48
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. ( 29939876 )
2018
49
Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. ( 28796414 )
2018
50
Mucosal Melanoma: a Literature Review. ( 29569184 )
2018

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh37 Chromosome 15, 48738898: 48738898
2 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh38 Chromosome 15, 48446701: 48446701
3 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh38 Chromosome 9, 21971162: 21971162
4 CDKN2A NM_000077.4(CDKN2A): c.197A> C (p.His66Pro) single nucleotide variant Uncertain significance rs756750256 GRCh37 Chromosome 9, 21971161: 21971161
5 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh38 Chromosome 13, 32336418: 32336418
6 BRCA2 NM_000059.3(BRCA2): c.2063A> G (p.Tyr688Cys) single nucleotide variant Uncertain significance rs28897713 GRCh37 Chromosome 13, 32910555: 32910555

Cosmic variations for Melanoma:

9 (show top 50) (show all 537)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM231655 PREX2 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 8:68097179-68097179 11
2 COSM231663 PREX2 skin,back,malignant melanoma,superficial spreading c.4165G>A p.E1389K 8:68146286-68146286 11
3 COSM1756934 NF1 skin,back,malignant melanoma,nodular c.3028C>T p.Q1010* 17:31230297-31230297 11
4 COSM1651647 KIT skin,eye,malignant melanoma,NS c.1459G>A p.G487S 4:54725969-54725969 11
5 COSM476 BRAF skin,back,malignant melanoma,superficial spreading c.1799T>A p.V600E 7:140753336-140753336 11
6 COSM1139 BRAF skin,back,malignant melanoma,superficial spreading c.1840T>C p.S614P 7:140753295-140753295 11
7 COSM231656 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 8:68097179-68097179 11
8 COSM10863 TP53 skin,back,malignant melanoma,NS c.833C>T p.P278L 17:7673787-7673787 10
9 COSM5610575 RUNX1T1 skin,back,malignant melanoma,NS c.206C>T p.S69F 8:92014730-92014730 10
10 COSM5610538 RPTOR skin,back,malignant melanoma,NS c.484G>A p.G162R 17:80707976-80707976 10
11 COSM131810 ROR2 skin,back,malignant melanoma,NS c.1172T>C p.V391A 9:91730921-91730921 10
12 COSM142708 PTPRT skin,back,malignant melanoma,NS c.2779G>A p.D927N 20:42141972-42141972 10
13 COSM142711 PTPRT skin,back,malignant melanoma,NS c.4372G>A p.E1458K 20:42080899-42080899 10
14 COSM5610410 PTPRK skin,back,malignant melanoma,NS c.3251+2T>A p.? 6:127985719-127985719 10
15 COSM5610413 PTPRK skin,back,malignant melanoma,NS c.3894C>T p.I1298I 6:127976732-127976732 10
16 COSM142789 PTPRH skin,back,malignant melanoma,NS c.2969C>T p.P990L 19:55185595-55185595 10
17 COSM5610296 PTPRD skin,back,malignant melanoma,NS c.3487G>A p.E1163K 9:8471012-8471012 10
18 COSM142712 PTPRD skin,back,malignant melanoma,NS c.182G>A p.G61E 9:8636727-8636727 10
19 COSM142819 PTPN12 skin,back,malignant melanoma,NS c.1448C>T p.S483L 7:77627127-77627127 10
20 COSM142820 PTPN12 skin,back,malignant melanoma,NS c.2314C>T p.P772S 7:77639251-77639251 10
21 COSM5610076 PTK2B skin,back,malignant melanoma,NS c.596C>T p.S199F 8:27430137-27430137 10
22 COSM231661 PREX2 skin,back,malignant melanoma,NS c.4066G>A p.E1356K 8:68138496-68138496 10
23 COSM5609955 PLCG1 skin,back,malignant melanoma,NS c.1161G>A p.K387K 20:41164145-41164145 10
24 COSM760 PIK3CA skin,back,malignant melanoma,NS c.1624G>A p.E542K 3:179218294-179218294 10
25 COSM4713314 PDGFRB skin,back,malignant melanoma,NS c.3058G>A p.D1020N 5:150117697-150117697 10
26 COSM5609727 PAK3 skin,back,malignant melanoma,NS c.1015T>C p.W339R 23:111194323-111194323 10
27 COSM1294479 PAK3 skin,back,malignant melanoma,NS c.525T>A p.D175E 23:111162971-111162971 10
28 COSM131783 NTRK1 skin,back,malignant melanoma,NS c.1137G>A p.M379I 1:156873919-156873919 10
29 COSM5609593 NOTCH1 skin,back,malignant melanoma,NS c.5414T>C p.L1805P 9:136502059-136502059 10
30 COSM7002402 MTOR skin,back,malignant melanoma,NS c.1654C>T p.L552F 1:11240435-11240435 10
31 COSM142824 MTMR6 skin,back,malignant melanoma,NS c.1116G>C p.W372C 13:25254414-25254414 10
32 COSM142797 MTMR3 skin,back,malignant melanoma,NS c.1548C>A p.F516L 22:30016572-30016572 10
33 COSM142056 MMP2 skin,back,malignant melanoma,NS c.251C>T p.P84L 16:55483006-55483006 10
34 COSM5609183 JAK1 skin,back,malignant melanoma,NS c.392C>T p.P131L 1:64873461-64873461 10
35 COSM141885 GRM8 skin,back,malignant melanoma,NS c.776C>T p.P259L 7:126904635-126904635 10
36 COSM1698831 GRM3 skin,back,malignant melanoma,NS c.2230G>A p.D744N 7:86839744-86839744 10
37 COSM3412421 GRM3 skin,back,malignant melanoma,NS c.769G>A p.D257N 7:86786561-86786561 10
38 COSM108601 GRIN2A skin,back,malignant melanoma,NS c.3221C>T p.P1074L 16:9764323-9764323 10
39 COSM5609005 GRIN2A skin,back,malignant melanoma,NS c.3877G>A p.D1293N 16:9763667-9763667 10
40 COSM107381 GRIN2A skin,back,malignant melanoma,NS c.3523G>A p.E1175K 16:9764021-9764021 10
41 COSM131726 FLT1 skin,back,malignant melanoma,NS c.3241G>A p.D1081N 13:28319468-28319468 10
42 COSM107683 FLT1 skin,back,malignant melanoma,NS c.2827G>A p.E943K 13:28322916-28322916 10
43 COSM131721 FER skin,back,malignant melanoma,NS c.1739G>A p.G580D 5:109044705-109044705 10
44 COSM131769 ERBB4 skin,back,malignant melanoma,NS c.1472G>A p.R491K 2:211701984-211701984 10
45 COSM5608661 ERBB4 skin,back,malignant melanoma,NS c.2063G>A p.R688K 2:211630478-211630478 10
46 COSM5608659 ERBB4 skin,back,malignant melanoma,NS c.1600G>A p.E534K 2:211679074-211679074 10
47 COSM5608564 EPHB4 skin,back,malignant melanoma,NS c.2826C>T p.I942I 7:100805174-100805174 10
48 COSM131751 EPHB2 skin,back,malignant melanoma,NS c.614C>T p.A205V 1:22784879-22784879 10
49 COSM131747 EPHB1 skin,back,malignant melanoma,NS c.2432G>A p.G811E 3:135241233-135241233 10
50 COSM3630609 EPHA7 skin,back,malignant melanoma,NS c.1807C>T p.P603S 6:93259471-93259471 10

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

37
# Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MIR193B MIR205 MIR221 MIR222 MIR23B MIR34A
2 10.83 MIR221 MIR222 MIR23B

GO Terms for Melanoma

Cellular components related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 CCL27 CXCL8 FBN1 MIR182 MIR205 MIR221
2 micro-ribonucleoprotein complex GO:0035068 9.23 MIR182 MIR193B MIR205 MIR221 MIR222 MIR23B

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 CDKN2B-AS1 MIR182 MIR23B MIR34A
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 MIR221 MIR222 MIR23B MIRLET7B
3 negative regulation of angiogenesis GO:0016525 9.72 MIR222 MIR34A STAT1
4 miRNA mediated inhibition of translation GO:0035278 9.69 MIR182 MIR221 MIR222
5 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.57 MIR23B MIRLET7B
6 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.56 MIR182 MIR34A
7 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.54 MIR221 MIR222
8 negative regulation of sprouting angiogenesis GO:1903671 9.54 MIR221 MIR23B MIR34A
9 positive regulation of erythrocyte differentiation GO:0045648 9.5 MIR221 MIR222 STAT1
10 negative regulation by host of viral genome replication GO:0044828 9.49 MIR221 MIR222
11 positive regulation of axon regeneration GO:0048680 9.48 MIR221 MIR222
12 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.46 MIR221 MIR222
13 negative regulation of cell adhesion molecule production GO:0060354 9.43 MIR221 MIR222
14 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR221 MIR222
15 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.26 MIR221 MIR222
16 gene silencing by miRNA GO:0035195 9.23 MIR182 MIR193B MIR205 MIR221 MIR222 MIR23B
17 positive regulation of Schwann cell migration GO:1900149 9.16 MIR221 MIR222
18 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 8.96 MIR221 MIR222

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.17 MIR182 MIR193B MIR221 MIR222 MIR23B MIR34A

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....